Wall Street Beat
Listen to Stryker’s Q1 2014 earnings call
Recall charges continue to suck up Stryker’s profits
Intuitive Surgical sinks following rough Q1 report
Intuitive Surgical (NSDQ:ISRG) dropped more than 11% today as Wall Street reacted to the surgical systems maker’s disappointing 1st-quarter earnings.
Allergan resists $47B offer by swallowing poison pill
FDA clears Intuitive Surgical’s single-site da Vinci Sp robotic surgery system
Intuitive Surgical (NSDQ:ISRG) shares recouped some recent losses today after the medical device company announced 510(k) clearance from the FDA for its da Vinci Sp single-site robot-assisted surgery platform in urological procedures.
K2M’s IPO could reap as much as $183M
K2M Group Holdings, the largest privately held spinal implant maker, said today that its forthcoming initial public offering could be worth up to $183 million.
K2M announced its plans for a U.S. IPO early this year, saying in March that the launch could be worth $100 million.
Vital Therapies aims even lower with $12-per-share IPO | MassDevice.com On Call
MASSDEVICE ON CALL — California biotherapeutics company Vital Therapies dropped its per-share price even lower, opening today at $12 per share in the hopes of raising $54 million. Shares are slated to open today on the Nasdaq market under the symbol "VTL."
Cardiac Dimensions closes $20M equity round
Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.
M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, according to a press release. Investors in Australia, the U.S. and Canada also participated, the company said.
Mainstay Medical readies European IPO
Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.
Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.